A phase III clinical trial of Ryaltris (Mometasone/olopatadine) in china
Latest Information Update: 07 Oct 2021
At a glance
- Drugs Mometasone/olopatadine (Primary)
- Indications Allergic rhinitis
- Focus Therapeutic Use
- 07 Oct 2021 New trial record
- 30 Sep 2021 According to a Glenmark Pharmaceuticals media release, company finalized the Phase 3 protocol for China, and submitted the IND application in July 2021.